Berlin, Germany, and Nevada, USA, November 23, 2015 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, announced today that MagForce USA, Inc., MagForce AG’s US subsidiary, has successfully installed the first clinical NanoActivator(R) in the USA. This NanoActivator(R) is similar in design to the five NanoActivator(R) devices operating at University Hospitals in Germany applying NanoTherm(TM) Therapy for the treatment of Brain Tumors. However, the USA NanoActivator(R) has been modified to apply NanoTherm(TM) Therapy for the treatment of Prostate Cancer in addition to the treatment of Brain Tumors.
The USA NanoActivator(R) is located in Seattle, Washington, near the University of Washington Medical Center, and will be utilized in the Focal Thermal Ablation Registriation Study for Prostate Cancer for which the Company has filed an Investigational Device Exemption (IDE) with The US Food and Drug Administration (FDA) in May 2015. About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group’s proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.
NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
For more information, please visit: www.magforce.com.
